|The full article is available to subscribers||Subscriber Login|
Mild to moderate psoriasis is generally treated with topical corticosteroids. Vitamin D analogs and tazarotene are topical alternatives that can be used in combination with topical corticosteroids. Phototherapy and systemic therapy, including biologic agents, are recommended for patients with moderate to severe disease.
Drugs for psoriatic arthritis are reviewed in a separate article available at http://medicalletter.org/TML-article-1470d.
TOPICAL THERAPY — Corticosteroids – Topical corticosteroids are widely used for treatment of psoriasis both alone and in combination with phototherapy and systemic therapy. Ointments are generally the most effective. Foams and sprays can be applied to large areas, but the alcohol base used in many of them may cause burning in patients with sensitive skin.
Adverse Effects – Superpotent topical corticosteroids, such... more
- MB Hoffman et al. Psoriasis during pregnancy: characteristics and important management recommendations. Expert Rev Clin Immunol 2015; 11:709.
- Calcipotriene for psoriasis. Med Lett Drugs Ther 1994; 36:70.
- A betamethasone-calcipotriene combination for psoriasis. Med Lett Drugs Ther 2006; 48:55.
- Calcitriol (Vectical) for mild to moderate plaque psoriasis. Med Lett Drugs Ther 2009; 51:70.
- W Abramovits. Calcitriol 3 microg/g ointment: an effective and safe addition to the armamentarium in topical psoriasis therapy. J Drugs Dermatol 2009; 8(8 Suppl):s17.
- Two new retinoids for psoriasis. Med Lett Drugs Ther 1997; 39:105.
- A Menter et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009; 60:643.
- X Chen et al. Narrow-band ultraviolet B phototherapy versus broadband ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis. Cochrane Database Syst Rev 2013; 10:CD009481.
- MB Totonchy and MW Chiu. UV-based therapy. Dermatol Clin 2014; 32:399.
- S Lee et al. Biologic and nonbiologic systemic agents and phototherapy for treatment of chronic plaque psoriasis [Internet]. AHRQ Comparative Effectiveness Reviews 2012 Nov. Report No.12(13)-EHC144-EF.
- J Schmitt et al. Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2014; 170:274.
- VM Heydendael et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349:658.
- I Flyström et al. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008; 158;116.
- JC Cather and JJ Crowley. Use of biologic agents in combination with other therapies for the treatment of psoriasis. Am J Clin Dermatol 2014; 15:467.
- P Sator et al. Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics. J Eur Acad Dermatol Venereol 2015 February 9 (epub).
- IH Kim et al. Comparative efficacy of biologics in psoriasis: a review. Am J Clin Dermatol 2012; 13:365.
- RE Kalb et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and regiatryy (PSOLAR). JAMA Dermatol 2015 May 13 (epub).
- AL Semble et al. Safety and tolerability of tumor necrosis factor-α inhibitors in psoriasis: a narrative review. Am J Clin Dermatol 2014; 15:37.
- L Hsu et al. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol 2014; 170:261.
- Ustekinumab (Stelara) for psoriasis. Med Lett Drugs Ther 2010; 52:7.
- KA Papp et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371:1675.
- CE Griffiths et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362:118.
- C Paul et al. Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT). Br J Dermatol 2014; 170:425.
- Secukinumab (Cosentyx) for psoriasis. Med Lett Drugs Ther 2015; 57:45.
- A Blauvelt et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol 2015; 172:484.
- C Paul et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol 2015; 29:1082.
- RG Langley et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med 2014; 371:326.
- D Thaci et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: 16 week results from the CLEAR study. Presented at American Academy of Dermatology 73rd Annual Meeting. San Francisco, CA, March 20, 2015.
- Tofacitinib (Xeljanz) for rheumatoid arthritis. Med Lett Drugs Ther 2013; 55:1.
- A Chiricozzi et al. Tofacitinib for the treatment of moderate-to-severe psoriasis. Expert Rev Clin Immunol 2015; 11:443.